Hemeo President & CEO Lee DeGeer Presented Live at LSI USA ’26, Showcasing Breakthrough Innovation in Clinical Decision Support for Coagulation Management.

Hemeo, a clinical decision support (CDS) company advancing precision coagulation management, announced that Lee DeGeer, President and Chief Executive Officer, presented live on stage at LSI USA ’26, one of the premier global conferences for emerging medtech and digital health innovation.

During his presentation, DeGeer introduced Hemeo’s vision for transforming coagulation decision‑making through advanced analytics, real‑time clinical insights, and a two‑phase regulatory strategy designed to accelerate adoption while building toward a fully regulated AI‑enabled SaMD platform.

The presentation highlighted:

• Hemeo Vantage™ Version 1.0, the company’s initial CDS software designed to operate under FDA’s Non‑Device CDS enforcement discretion pathway
• The company’s Phase 2 roadmap, including its planned AI‑enabled premium offering intended for a De Novo Class II submission
• The significant clinical and economic burden of transfusion variability across U.S. hospitals
• Hemeo’s multi‑year strategy to generate high‑quality evidence through leading academic medical centers in the United States and Europe
• The company’s long‑term vision for improving patient outcomes, reducing unnecessary transfusions, and supporting hospitals with measurable cost savings

“LSI brings together the most forward‑thinking leaders in medtech, and it’s an ideal venue to share how Hemeo is addressing one of the most persistent and costly challenges in acute care,” said Lee DeGeer, President & CEO of Hemeo. “Our mission is to give clinicians the clarity they need at the moment it matters most. We’re excited to show how our platform can help hospitals improve outcomes, reduce variability, and deliver more precise, data‑driven care.”

About Hemeo

Hemeo is a clinical decision support company focused on improving coagulation management through advanced analytics, real‑time insights, and evidence‑based decision support. The company’s platform is designed to help clinicians reduce transfusion variability, improve patient outcomes, and support hospitals with measurable economic value. Hemeo is headquartered in Broken Arrow, Oklahoma, with research and clinical collaborations across the United States and Europe.